Answers are grounded in this paper and cite their sources.
Metal-organic frameworks (MOFs) have emerged as highly versatile nanoporous materials for nanomedicine owing to their exceptionally high surface area, tunable pore architecture, controllable surface chemistry, and stimuli-responsive drug release. These nanoscale characteristics enable efficient encapsulation of poorly soluble therapeutics, targeted delivery, and controlled release while minimizing systemic toxicity. Pulmonary delivery has gained increasing attention as an approach for localized treatment of inflammatory lung diseases. In parallel, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway has been established as a key regulator of cytokine-mediated inflammation in severe asthma, although systemic administration of JAK inhibitors remains limited by immunosuppression and dose-dependent adverse effects. While MOFs have demonstrated considerable promise as pulmonary drug delivery systems and JAK inhibitors have shown therapeutic potential in inflammatory airway diseases, no published study has directly investigated MOF-mediated pulmonary delivery of JAK inhibitors for asthma. This review critically examines the current evidence supporting both fields and proposes a conceptual framework for integrating these technologies. Specifically, it discusses the nanoscale design principles of MOFs, including structural engineering, pore modulation, physicochemical characteristics, biodegradability, and pulmonary delivery strategies relevant to inhaled nanomedicine. Recent advances in MOF-based drug delivery, preclinical evidence, comparisons with conventional nanocarriers, and emerging approaches involving biomimetic coatings, hybrid nanocomposites, and artificial intelligence-assisted nanomaterial design are critically evaluated. Current challenges, including pulmonary biocompatibility, long-term nanotoxicity, scalable manufacturing, immune interactions, and regulatory considerations, are also discussed. By distinguishing established evidence from future opportunities, this review identifies MOF-mediated pulmonary delivery of JAK inhibitors as a promising yet experimentally unvalidated strategy and outlines key research priorities required for its successful translation toward precision therapy for severe asthma. Clinical trial number: NA
No takes yet. Share an insight, caveat, or question.
Wankhede et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: